Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Paganelli

Showing results (41-50 of 213) with videos related to

Pageof 22
Sort By:
La Radiologia Medica|August 18, 2018
<sup>68</sup>Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancerSimona Malaspina, Ugo De Giorgi, Jukka Kemppainen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2005
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapyDavid M Goldenberg, Robert M Sharkey, Giovanni Paganelli, et al.
Annals of Hematology|April 22, 2011
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapyAndrea Piccin, Chiara Maria Grana, Giovanni Negri, et al.
International Journal of Molecular Sciences|March 10, 2022
On the Way for Patients with Prostate Cancer to the Best Use of PSMAFinn Edler von Eyben, Glenn Bauman, Daniel S Kapp, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 20, 2004
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumoursLisa Bodei, Marta Cremonesi, Chiara Grana, et al.
Scientific Reports|January 8, 2022
Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical deviceAnna Sarnelli, Matteo Negrini, Emilio Mezzenga, et al.
In Vivo (Athens, Greece)|September 13, 2022
<i>In Vivo</i> Models for the Performance and Safety of BAT-90, a Novel 90-Yttrium-based Internal Radiotherapy PlatformAntonino Amato, Gordon McVie, Giovanni Paganelli, et al.
Cancer Treatment Reviews|February 29, 2024
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkersEmilio Francesco Giunta, Nicole Brighi, Giorgia Gurioli, et al.
Molecules (Basel, Switzerland)|July 9, 2022
Production and Quality Control of [<sup>177</sup>Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical TrialsValentina Di Iorio, Stefano Boschi, Cristina Cuni, et al.
Transplantation|March 17, 2004
Targeted bone marrow radioablation with 153Samarium-lexidronam promotes allogeneic hematopoietic chimerism and donor-specific immunologic hyporesponsivenessLuca Inverardi, Elina Linetsky, Antonello Pileggi, et al.
Pageof 22

Showing results (41-50 of 213) with videos related to

Sort By:
Pageof 22
La Radiologia Medica|August 18, 2018
<sup>68</sup>Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancerSimona Malaspina, Ugo De Giorgi, Jukka Kemppainen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2005
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapyDavid M Goldenberg, Robert M Sharkey, Giovanni Paganelli, et al.
Annals of Hematology|April 22, 2011
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapyAndrea Piccin, Chiara Maria Grana, Giovanni Negri, et al.
International Journal of Molecular Sciences|March 10, 2022
On the Way for Patients with Prostate Cancer to the Best Use of PSMAFinn Edler von Eyben, Glenn Bauman, Daniel S Kapp, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 20, 2004
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumoursLisa Bodei, Marta Cremonesi, Chiara Grana, et al.
Scientific Reports|January 8, 2022
Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical deviceAnna Sarnelli, Matteo Negrini, Emilio Mezzenga, et al.
In Vivo (Athens, Greece)|September 13, 2022
<i>In Vivo</i> Models for the Performance and Safety of BAT-90, a Novel 90-Yttrium-based Internal Radiotherapy PlatformAntonino Amato, Gordon McVie, Giovanni Paganelli, et al.
Cancer Treatment Reviews|February 29, 2024
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkersEmilio Francesco Giunta, Nicole Brighi, Giorgia Gurioli, et al.
Molecules (Basel, Switzerland)|July 9, 2022
Production and Quality Control of [<sup>177</sup>Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical TrialsValentina Di Iorio, Stefano Boschi, Cristina Cuni, et al.
Transplantation|March 17, 2004
Targeted bone marrow radioablation with 153Samarium-lexidronam promotes allogeneic hematopoietic chimerism and donor-specific immunologic hyporesponsivenessLuca Inverardi, Elina Linetsky, Antonello Pileggi, et al.
Pageof 22